SBL
DTIL icon

Sargent Bickham Lagudis’s Precision BioSciences DTIL Stock Holding History

Sargent Bickham Lagudis’s Portfolio DTIL Stock Details DTIL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-7
Closed -$2K – 940
2021
Q1 		$2K Hold
7
– – ﹤0.01% 855
2020
Q4 		$2K Buy
+7
New +$1.72K ﹤0.01% 806

Other funds holding DTIL

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Sargent Bickham Lagudis's DTIL Position: Q2 2021 in Review

Sargent Bickham Lagudis sold out of Precision BioSciences (DTIL) in Q2 2021, closing a stake of 7 shares — an estimated $2K sold.

Sargent Bickham Lagudis first reported a position in DTIL in Q4 2020 and held it in 2 quarters. The position peaked at $2K in Q1 2021. 130 funds tracked by Wall St. Rank hold DTIL as of Q2 2021.

  • Sargent Bickham Lagudis reported no remaining Precision BioSciences position as of Q2 2021 after selling out during the quarter.
  • Sargent Bickham Lagudis sold 7 Precision BioSciences shares in Q2 2021, an estimated $2K.
  • Sargent Bickham Lagudis first reported a position in Precision BioSciences in Q4 2020 and held it in 2 quarters.
  • Sargent Bickham Lagudis's Precision BioSciences position peaked at $2K in Q1 2021.
  • 130 funds tracked by Wall St. Rank held Precision BioSciences as of Q2 2021.

Based on Sargent Bickham Lagudis's 13F filing for Q2 2021, filed 19 Jul 2021.